Friday, July 10, 2026

Drug profile · INN

ly01610 ( irinotecan hydrochloride liposome injection )

ly01610 ( irinotecan hydrochloride liposome injection ) is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — ly01610 ( irinotecan hydrochloride liposome injection )
Class
Route
Patents
0
Programs
4
Data quality
0.70

Quick answer

ly01610 ( irinotecan hydrochloride liposome injection ) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN ly01610 ( irinotecan hydrochloride liposome injection )

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. 610 Phase 3 · Sunshine Guojian Pharmaceutical · Asthma
  2. 610 100mg Phase 2 · Sunshine Guojian Pharmaceutical · Asthma
  3. 610 Phase 1 · Sunshine Guojian Pharmaceutical · add-on Maintenance Treatment of Patients With Severe Eosinop
  4. 610 30mg group Phase 1 · Sunshine Guojian Pharmaceutical · Asthma

Frequently asked questions

What is ly01610 ( irinotecan hydrochloride liposome injection )?

ly01610 ( irinotecan hydrochloride liposome injection ) is an FDA-listed pharmaceutical active ingredient.